This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 118/18/1817    most recent CIRCULATIONAHA.108.781377v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mauri, L. Articles by Normand, S.-L. T. Search for Related Content PubMed PubMed Citation Articles by Mauri, L. Articles by Normand, S.-L. T. Pubmed/NCBI databases Medline Plus Health Information Angioplasty Coronary Artery Disease Related Collections Health policy and outcome research Catheter-based coronary interventions: stents Related Article

(Circulation. 2008;118:1817-1827.)
© 2008 American Heart Association, Inc.

Interventional Cardiology

Long-Term Clinical Outcomes After Drug-Eluting and Bare-Metal Stenting in Massachusetts

Laura Mauri, MD, MSc; Treacy S. Silbaugh, BSc; Robert E. Wolf, MS; Katya Zelevinsky, BA; Ann Lovett, RN, MA; Zheng Zhou, MD, PhD; Frederic S. Resnic, MD, MSc; Sharon-Lise T. Normand, PhD

From Brigham and Women’s Hospital (L.M., Z.Z., F.S.R.) and Harvard Clinical Research Institute (L.M.); Harvard Medical School (L.M., T.S.S., R.E.W., K.Z., A.L., F.S.R., S.-L.T.N.); and Harvard School of Public Health (S.-L.T.N.), Boston, Mass.

Correspondence to Laura Mauri, MD, MSc, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115. E-mail lmauri1{at}partners.org

Received March 20, 2008; accepted August 19, 2008.

Background— Drug-eluting stents (DES) reduce the need for repeat revascularization, but their long-term safety relative to that of bare-metal stents (BMS) in general use remains uncertain. We sought to compare the clinical outcome of patients treated with DES with that of BMS.

Methods and Results— All adults undergoing percutaneous coronary intervention with stenting between April 1, 2003, and September 30, 2004, at non–US government hospitals in Massachusetts were identified from a mandatory state database. Patients were classified from the index admission according to stent types used. Clinical and procedural risk factors were collected prospectively. Risk-adjusted mortality, myocardial infarction, and revascularization rate differences (DES–BMS) were estimated through propensity score matching without replacement. A total of 11 556 patients were treated with DES, and 6237 were treated with BMS, with unadjusted 2-year mortality rates of 7.0% and 12.6%, respectively (P<0.0001). In 5549 DES patients matched to 5549 BMS patients, 2-year risk-adjusted mortality rates were 9.8% and 12.0%, respectively (P=0.0002), whereas the respective rates for myocardial infarction and target-vessel revascularization were 8.3% versus 10.3% (P=0.0005) and 11.0% versus 16.8% (P<0.0001).

Conclusions— DES treatment was associated with lower rates of mortality, myocardial infarction, and target-vessel revascularization than BMS treatment in similar patients in a matched population-based study. Comprehensive follow-up in this inclusive population is warranted to identify whether similar safety and efficacy remain beyond 2 years.

---

 

CLINICAL PERSPECTIVE

Related Article:

Clinical Summaries
Circulation 2008 118: 1777-1778. [Extract] [Full Text]

This article has been cited by other articles:

				S. R. Dixon, C. L. Grines, and W. W. O'Neill The year in interventional cardiology. J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2080 - 2097. [Full Text] [PDF]

				D. T. Ko, M. Chiu, H. Guo, P. C. Austin, R. Goeree, E. Cohen, M. Labinaz, and J. V. Tu Safety and effectiveness of drug-eluting and bare-metal stents for patients with off- and on-label indications. J. Am. Coll. Cardiol., May 12, 2009; 53(19): 1773 - 1782. [Abstract] [Full Text] [PDF]

				S. K. James, U. Stenestrand, J. Lindback, J. Carlsson, F. Schersten, T. Nilsson, L. Wallentin, B. Lagerqvist, and the SCAAR Study Group Long-Term Safety and Efficacy of Drug-Eluting versus Bare-Metal Stents in Sweden N. Engl. J. Med., May 7, 2009; 360(19): 1933 - 1945. [Abstract] [Full Text] [PDF]

				B. Horst, C. S. Rihal, D. R. Holmes Jr, J. F. Bresnahan, A. Prasad, G. Gau, R. Lennon, and A. Lerman Comparison of Drug-Eluting and Bare-Metal Stents for Stable Coronary Artery Disease J. Am. Coll. Cardiol. Intv., April 1, 2009; 2(4): 321 - 328. [Abstract] [Full Text] [PDF]

				R. J. Applegate, M. T. Sacrinty, M. A. Kutcher, R. M. Santos, S. K. Gandhi, and W. C. Little 3-Year Comparison of Drug-Eluting Versus Bare-Metal Stents J. Am. Coll. Cardiol. Intv., March 1, 2009; 2(3): 231 - 239. [Abstract] [Full Text] [PDF]

				Effect of Length and Diameter of Drug-Eluting Stents Versus Bare-Metal Stents on Late Outcomes Circ Cardiovasc Interv, February 1, 2009; 2(1): 35 - 42.

				B. Y.L. Wong, D. H. Kim, K. J. Rothman, L. Mauri, and S.-L. T. Normand Drug-eluting versus bare-metal stents in acute myocardial infarction. N. Engl. J. Med., January 15, 2009; 360(3): 300 - 301. [Full Text] [PDF]

				D. E. Cutlip Drug-Eluting or Bare-Metal Stents for ST Elevation Myocardial Infarction Can Observational Data Balance the Risk Benefit Equation? Circ Cardiovasc Interv, December 1, 2008; 1(3): 161 - 163. [Full Text] [PDF]

				P. Garg, S.-L. T. Normand, T. S. Silbaugh, R. E. Wolf, K. Zelevinsky, A. Lovett, M. R. Varma, Z. Zhou, and L. Mauri Drug-Eluting or Bare-Metal Stenting in Patients With Diabetes Mellitus: Results From the Massachusetts Data Analysis Center Registry Circulation, November 25, 2008; 118(22): 2277 - 2285. [Abstract] [Full Text] [PDF]

				S. B. King III and E. L. Hannan Mounting Evidence for Safety and Improved Outcomes of Drug-Eluting Stenting: But Is It the Stent? Circulation, October 28, 2008; 118(18): 1783 - 1784. [Full Text] [PDF]